Orchid Pharma shares hit upper circuit on buyback of rights to novel antibiotic

The company announced the acquisition of 100% global ownership of its novel antibiotic Enmetazobactam, which was originally discovered and developed in-house.

Leave a Reply

Your email address will not be published. Required fields are marked *